gutflix
GI learning, personalised

Summary

LINAPRAZAN GLURATE IS HIGHLY EFFECTIVE IN TREATING MODERATE TO SEVERE EROSIVE ESOPHAGITIS: A DOUBLE-BLIND, RANDOMIZED, DOSE FINDING STUDY

Peter Unge

UEG Week Copenhagen 2023 | Poster

Oesophagus

October 15, 2023

Phase 2 dose-finding study of linaprazan glurate, a potassium competitive acid blocker, demonstrated 4-week healing rates of 73.6% in moderate to severe erosive esophagitis (LA grade C/D) compared to 37.5% with lansoprazole, with the highest healing rate observed at 75 mg twice daily.

KEY POINTS

- 248 patients with endoscopically confirmed erosive esophagitis were randomized to linaprazan glurate at 25 mg, 50 mg, 75 mg, or 100 mg twice daily or lansoprazole 30 mg once daily in a double-blind active comparator-controlled study
- In LA grade C/D patients, linaprazan glurate 75 mg twice daily achieved the highest healing rate at 89.5% after 4 weeks, showing a clear dose-response trend from 25 mg to 75 mg
- For LA grade A/B patients, linaprazan glurate achieved 4-week healing rates of 83.8% compared to 81.0% with lansoprazole
- The study supports dose selection for Phase 3 trials and further development of linaprazan glurate for treatment of erosive esophagitis due to GERD

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/6bae95b0-743b-11ee-94fc-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.